Carol Hamilton, MD, MHS
Director, Scientific AffairsAreas of expertise
- Tuberculosis prevention, care and treatment, research and programs
- Infectious diseases
- HIV/AIDS
- TB-HIV co-infection research and programs
- Vaccine-preventable diseases
- Neglected tropical diseases
- Global public health and development
Projects & Resources
-
The global resurgence of tuberculosis (TB) over the past decades has been fueled by emerging drug resistance, co-infection with increasingly prevalent HIV and decreasing investments in public health systems.
-
FHI 360 is a member of the Tuberculosis Trials Consortium (TBTC), which conducts clinical, laboratory and epidemiologic research for the diagnosis, clinical management and prevention of TB infection and disease.
-
September 2012 — These tools were developed under TB CAP and TB CARE 1 core-funded projects.
-
HIV infection is the strongest risk factor for a person to develop tuberculosis (TB), and TB is responsible for over a quarter of all AIDS-related deaths worldwide.
-
September 2011 — Providing isoniazid to prevent tuberculosis among people living with HIV is a proven, internationally recommended strategy that has been effectively implemented in low-resource settings.
Published Research
-
Developing a framework for evaluating ethical outcomes of good participatory practices in TB clinical drug trials
MacQueen KM, Eley NT, Frick M, Mingote LR, Chou A, Seidel SS, Hannah S, Hamilton C
J Empir Res Hum Res Ethics 2016 Jul; 11(3): 203-13. [Journal Impact Factor: 1.146]
With the growing acceptance of community engagement and participatory strategies in clinical research, evaluation of the benefits and burdens are needed. Working with global tuberculosis (TB) stakeholders, the authors developed a theory of change evaluation framework for the Good Participatory Practice Guidelines for TB Drug Trials. The framework is a first step in systematically evaluating participatory research in clinical trials.
-
Adjuvant corticosteroid treatment in adults with influenza A (H7N9) viral pneumonia
Cao B, Gao H, Zhou B, Deng X, Hu C, Deng C, Lu H, Li Y, Gan J, Liu J, Li H, Zhang Y, Yang Y, Fang Q, Shen Y, Gu Q, Zhou X, Zhao W, Pu Z, Chen L, Sun B, Liu X, Hamilton CD, Li L
Crit Care Med 2016 Jun; 44 (6): e318-28. [Journal Impact Factor: 6.312]
This retrospective study of 288 adults and adolescents determined the impact of adjuvant corticosteroids administered to patients hospitalized with severe influenza A (H7N9) viral pneumonia in mainland China. The authors found that, contrary to expectations, high-dose corticosteroids were associated with increased mortality and longer viral shedding in patients with influenza A (H7N9) viral pneumonia. The authors conclude that corticosteroids are not indicated for use with this type of severe influenza.
-
Determining hepatitis C virus incidence in populations: An important tool of epidemic control (editorial)
Mastro TD, Morrison CS, Hamilton CD
Journal of Infectious Diseases. 2016; 214 (3): 339-40.
There are an estimated 130–150 million people living with chronic hepatitis C virus (HCV) infection worldwide. Traditional methods of incidence determination are complex and expensive, involving long-term, prospective follow-up of cohorts of HCV-negative persons. This editorial reviews the data of a multiassay algorithm for estimating the incidence of HCV infection; modeled after algorithms to determine HIV infection incidence from cross-sectional surveys. The authors present evidence that reinforces the need for improved HCV infection incidence estimates to assess progress made as increased investments are made in treatment and prevention programs.